View source for Oseltamivir

{{MedTemplate
| generic           = Oseltamivir
| brand             = Tamiflu
| structure         =
| classes           = [[:Category:Antivirals|Antiviral]], [[:Category:Neuraminidase_inhibitors|Neuraminidase inhibitor]], [[:Category:Anti-influenza_agents|Anti-influenza agent]]
| uses              = <vote slug="influenza-treatment-use">Influenza A and B treatment (within 48 hours of symptom onset)</vote>, <vote slug="influenza-prophylaxis-use">Post-exposure influenza prophylaxis</vote>, <vote slug="influenza-prophylaxis-outbreak-use">Outbreak control in long-term care facilities</vote>
| starting_dose     = Treatment: 75 mg PO BID × 5 days (adult); pediatric weight-based; prophylaxis: 75 mg PO once daily × 7-10 days
| preparations      = 30, 45, 75 mg capsules; 6 mg/mL oral suspension
| fda_max           = 150 mg/d (treatment)
| pill_id           =
| routes            = Oral
| onset             = Symptom shortening detectable within 24-48 hours of starting (small absolute benefit; ~1 day reduction in symptom duration)
| duration          = 12 hours
| halflife          = ~6-10 hours (oseltamivir carboxylate, the active metabolite)<ref name="tamiflu-label">FDA Prescribing Information, Tamiflu (oseltamivir phosphate), Genentech, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021087s066lbl.pdf</ref>
| bioavailability   = ~75% (oral, as the active carboxylate after hepatic esterase activation)<ref name="tamiflu-label" />
| pregnancy         = Generally used when influenza treatment is indicated; pregnancy is a recognized risk factor for severe influenza.{{citation needed}}
| legal             = [[USLegal:Prescription only|Rx-only]] in US
| mechanism         = <vote slug="oseltamivir-mech-claim">Oseltamivir is an ester prodrug activated by hepatic carboxylesterase to oseltamivir carboxylate, a competitive inhibitor of influenza A and B neuraminidase; blocking neuraminidase prevents sialic acid cleavage from host glycoproteins, trapping newly assembled virions on the cell surface and limiting spread to neighboring cells.</vote> Modest clinical benefit (~1 day faster symptom resolution in healthy adults treated within 48 hours); larger absolute benefit in hospitalized, high-risk, and severely ill patients. Neuropsychiatric events (delirium, abnormal behavior, especially in children) are FDA-labeled adverse effects of uncertain causal contribution<ref name="tamiflu-label" />.
}}

== References ==
<references />
[[Category:Antivirals]]
[[Category:Neuraminidase inhibitors]]
[[Category:Anti-influenza agents]]